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INTRODUCTION
Ischemic tolerance is the phenomenon whereby ischemic pre-
conditioning (IP) protects against a subsequent episode of lethal 
ischemia [1]. Endogenous mechanisms of IP lead to increased 
cellular resistance against ischemia after one or several episodes of 
transient ischemia. It has been shown that IP protects pyramidal 
cells in hippocampal CA1 from subsequent lethal ischemia [2]. 
The neuroprotective mechanism of IP is thought to occur via 
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Ischemic preconditioning (IP) is one of the most important endogenous mechanisms that protect the cells against ischemia-reper-
fusion (I/R) injury. However, the exact molecular mechanisms remain unclear. In this study, we showed that changes in the level of 
agmatine were correlated with ischemic tolerance. Changes in brain edema, infarct volume, level of agmatine, and expression of argi-
nine decarboxylase (ADC) and nitric oxide synthases (NOS; inducible NOS [iNOS] and neural NOS [nNOS]) were analyzed during 
I/R injury with or without IP in the rat brain. After cerebral ischemia, brain edema and infarct volume were significantly reduced in 
the IP group. The level of agmatine was increased before and during ischemic injury and remained elevated in the early reperfusion 
phase in the IP group compared to the experimental control (EC) group. During IP, the level of plasma agmatine was increased in 
the early phase of IP, but that of liver agmatine was abruptly decreased. However, the level of agmatine was definitely increased in the 
ipsilateral and contralateral hemisphere of brain during the IP. IP also increased the expression of ADC—the enzyme responsible for 
the synthesis of endogenous agmatine—before, during, and after ischemic injury. In addition, ischemic injury increased endogenous 
ADC expression in the EC group. The expression of nNOS was reduced in the I/R injured brain in the IP group. These results sug-
gest that endogenous increased agmatine may be a component of the ischemic tolerance response that is induced by IP. Agmatine 
may have a pivotal role in endogenous ischemic tolerance.
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numerous signal transduction pathways involved in cell protec-
tion. Heat shock proteins, immediate early genes, antioxidant 
enzymes, and anti-apoptotic pathways provide ischemic tolerance 
and increased cell survival after ischemia [3-5]. It is also thought to 
involve endoplasmic reticulum and DNA repair mechanisms [6]. 
However, the exact molecular mechanisms remain unclear despite 
the many numbers of studies.
Agmatine, a molecule synthesized via decarboxylation of L-
arginine by arginine decarboxylase (ADC), is hydrolyzed to pu-
trescine and urea by agmatinase [7, 8]. Several research groups, 
including ours, have reported that agmatine, ADC, and agmatinase 
are found in different regions of the mammalian brain, where they 
provide neuroprotection against various types of cerebral injury 
[9]. Agmatine is an endogenous clonidine-displacing substance, 
an agonist for the α2-adrenergic and imidazoline receptors, and an 
antagonist for the N-methyl-D-aspartate (NMDA) receptors [9-
12]. Recent studies have shown that agmatine may be neuropro-
tective in trauma and ischemia models [7, 13-19]. Agmatine pro-
tects neurons against glutamate toxicity, and this effect is mediated 
through NMDA receptor blockade, with agmatine interacting at a 
site located within the NMDA channel pore [20]. Being structural-
ly similar to L-arginine, agmatine is also a competitive nitric oxide 
synthase (NOS) inhibitor [21, 22]. NOS generate nitric oxide (NO) 
by subsequent oxidation of the guanidinium group in L-arginine, 
and agmatine is an L-arginine analog with a guanidinium group. 
Nitric oxide (NO) generated by NOS is known to trigger inflam-
mation and apoptosis after ischemic stroke [23]. 
We have previously reported that agmatine exerts neuroprotec-
tive functions by reducing the size of ischemic infarctions and 
preventing cerebral neuron loss by reducing NOS expression after 
focal or global ischemia [18, 24, 25]. These results suggested that 
agmatine protects the brain from ischemic injury by interfering 
with NO signaling. Based on the neuroprotective effects of agma-
tine in cerebral injuries, particularly cerebral ischemic injuries, it is 
important to investigate the changes in agmatine level and the role 
of agmatine in ischemic tolerance following IP for defining the 
protective mechanism of IP. Therefore, we performed this study 
to determine the effects of agmatine on ischemic tolerance after 
transient focal ischemia and to determine the systemic level of ag-
matine during ischemic injury.
MATERIALS AND METHODS
Experimental animals
Eight-week-old male Sprague-Dawley rats (SAMTAKO, Osan, 
South Korea) weighing 300±20 g were used for all experiments. 
Rats were allowed free access to food and water before the experi-
ments. Animals were anesthetized with Zoletil50 (0.6 mg/kg) and 
rompun (0.4 mg/kg) injected intramuscularly. Before and during 
any surgery, body temperature was maintained at 36.5~37.5oC. 
All animal procedures were carried out according to a protocol 
approved by the International Animal Care and Use Committee 
(IACUC) of Yonsei University Animal Research Center (YLARC, 
permission No. 2014-0375) using National Institutes of Health 
(NIH) guidelines. All of the animals were maintained in a specific 
pathogen-free facility of the YLARC.
Induction of IP and focal cerebral ischemia
Transient middle cerebral artery (MCA) occlusion was con-
ducted as described before [16]. In the IP group, a 60-min major 
occlusion was induced 3 days after a 10-min occlusion. In the 
experimental control (EC) group, a 60-min major occlusion was 
induced 3 days after the sham operation (Fig. 1A). In detail, a rat 
was anesthetized and placed in a stereotaxic frame. A craniectomy 
(3 mm in diameter, 6 mm lateral and 2 mm caudal to bregma) 
was performed with extreme care over the MCA territory using a 
trephine. The dura was left intact, and a laser Doppler flowmeter 
probe was placed on the surface of the ipsilateral cortex and fixed 
to the periosteum. The probe was connected to a laser flowmeter 
device (OMEGA FLOW, FLO-C1, Neuroscience, Tokyo, Japan) 
for continuous monitoring of regional cerebral blood flow (rCBF). 
The right common carotid artery (CCA), external carotid artery 
(ECA), and internal carotid artery (ICA) were exposed through a 
ventral midline incision. A 4-0 monofilament nylon suture with a 
rounded tip (around 160 μm in diameter) was introduced into the 
CCA lumen and gently advanced into the ICA until rCBF was re-
duced to 15~20% of the baseline (recorded by laser Doppler flow-
metry). After the desired period of occlusion (10 min or 1 hr), the 
suture was withdrawn to restore the blood flow (confirmed by the 
return of rCBF to the baseline level). The wound was sutured, and 
the rat was allowed to recover from anesthesia before returning to 
the cage with free access to rat chow and water. 
Morphometric measurement of brain edema and infarct 
volume
Animals were decapitated at 0, 1, 2, 4, 7, or 24 hr after ischemia 
and the brains were rapidly removed and sectioned coronally with 
2-mm intervals. The 2nd, 4th, and 6th sections of six serial slices were 
incubated for 30 min in a 2% 2,3,5-triphenyltetrazolium chloride 
(TTC) solution at 37oC and fixed in a 4% paraformaldehyde solu-
tion. Using a computerized image analysis system (Image J, version 
1.36, NIH, USA), the area of infarction of each section was mea-
sured. The volume of infarction in each animal was obtained from 
the product of slice thickness (2 mm) and the sum of infarction ar-
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eas in all brain slices examined. Brain edema was determinedfrom 
the following formula: Brain edema (%)=(the volume of ipsilateral 
hemisphere/the volume of contralateral hemisphere) ×100 (%).
Agmatine analysis with HPLC
Sample preparation
Brain, liver and plasma samples were prepared according to 
Fig. 1. IP reduced infarct size and brain edema in a rat model of MCAO. (A) Schematics of experimental IP in the rat brain. (B) The rCBF value was not 
significantly different between EC and IP groups during ischemic injury. Baseline values before MCAO were defined as 100% flow. (C) TTC staining 
of the ischemic injured brain of EC. (D) TTC staining of the ischemic injured brain with IP. (E and F) IP reduced the infarct volume and brain edema 
significantly compared to EC at R23. EC, experimental control; IP, ischemic preconditioning; NC, Normal Control; R0, 1 hr after MCAO; R1, 1 hr after 
reperfusion; R3, 3 hr after reperfusion; R6, 6 hr after reperfusion; R23, 23 hr after reperfusion (**p<0.05 vs. EC; ***p<0.01 vs. EC).
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the method of Reed and Belleroche with modification [26]. The 
ipsilateral part of 3rd brain coronal sections, liver, and plasma was 
quickly stored at -80oC until further use. Agmatine levels were 
determined by using high-performance liquid chromatography 
(HPLC) [27]. Briefly, tissue and plasma samples were weighed and 
homogenized in 0.5 ml of ice-cold 10% (w/v) trichloroacetic acid 
(TCA) per 150 mg tissue (wet weight) in ice. Sample homogenates 
were then left on ice for 1 hr and centrifuged at 20,000×g for 25 
min. The supernatant was washed five times using an equal vol-
ume of ice-cold diethyl-ether, and the aqueous phase was saved. 
Any remaining ether was evaporated at room temperature for 20 
min. A volume of 20 μl of TCA eluted sample and a volume of 
20 μl of the OPA-ME derivatizing reagent was mixed for 2 min at 
room temperature. Next, 20 μl was immediately injected into the 
HPLC system (Shimadzu, Kyoto, Japan).
Apparatus and chromatographic conditions
The HPLC system consisted of a pump and multi-solvent de-
livery system (Shimadzu HPLC CLASS-VP, Japan), a RF-10Axl 
fluorescence detector (the excitation wavelength of 325 nm and 
the emission wavelength of 425 nm; Shimadzu, Japan), and a Hy-
persil GOLD 150×2.1, 5-μm column (ThermoFisherScientific). 
Potassium borate buffer (final concentration 0.2 M, pH 9.4 at 
20oC) was prepared by dissolving boric acid in water and adjusting 
the pH with a saturated solution of potassium hydroxide in a final 
volume of 250 ml. The buffer was passed through a 0.22-μm filter 
(Gelman Sciences, MI, USA) and stored at 4oC. The OPA-ME de-
rivatizing reagent was prepared by dissolving 50 mg OPA in 1 ml 
of methanol and adding 53 μl of ME and 9 ml of 0.2 M potassium 
borate buffer (pH 9.4); the solution was stored at 4oC for not more 
than three days before use. Agmatine was measured by derivatiz-
ing with OPA-ME. The mobile phase consisted of a mixture of 
46% 10 mM potassium dihydrogen phosphate containing 3 mM 
octylsulfate sodium salt in water (pH 5.93), 34% acetonitrile, and 
20% methanol. The mobile phase was filtrated (FHLP04700, 0.45 
μm FH, Millipore) and degassed before use.
Quantification and statistical analysis
For the isocratic HPLC method, the concentration of agmatine 
in each sample was calculated by linear regression analysis of peak 
heights to the addition of varying concentrations of agmatine to 
samples [28].
Immunoblotting of ADC
Expression of ADC protein was estimated by immunoblotting 
in the ipsilateral part of 3rd brain coronal sections and the liver. 
Immunoblotting was performed using anti-ADC (ATGEN; 1:500, 
Gyeonggi-do, South Korea) and anti-actin (Santa Cruz; 1:500, TX, 
USA) antibodies. Equal amounts of protein (20 μg per condition) 
were separated on a 10% polyacrylamide gel and electro-trans-
ferred onto an Immobilon-P membrane (Millipore, Bedford, MA, 
USA). Immunoreactive bands were visualized with the ECL detec-
tion system (ThermoFisherScientific) using Kodak X-AR film.
Immunohistochemical staining for NOS
For immunohistochemistry, 6-μm 4th brain coronal sections were 
quickly fixed with 4% paraformaldehyde and embedded in paraf-
fin. Sections were immunostained with antibodies against nNOS 
(#06-528, Upstate; 1:200, MA, USA) or iNOS (#482728, Calbio-
chem; 1:200, CA, USA) followed by an appropriate biotinylated 
secondary antibody. Stains were visualized using the ABC kit (Vec-
tor, CA, USA), then reacted with diaminobenzidine (DAB, Sigma, 
St. Louis. MO, USA). Immunostaining controls were prepared by 
preparing sections without primary antibodies. All incubation 
steps were performed in a humidified chamber. The positive area 
was measured using a computerized image analysis system (Image 
J v1.36, NIH, USA).
Statistical analysis
Statistical tests to determine differences between groups were 
performed using the Student’s t-test using SPSS 13.0 (IBM, Chi-
cago, IL, USA). A p value<0.05 was considered significant. Data are 
expressed as the mean±standard deviation (SD), with the excep-
tion of HPLC results, for which the mean±standard error of the 
mean (SEM) is shown.
RESULTS
IP reduced injury after cerebral ischemia
The rCBF pattern measured using laser Doppler flowmetry over 
the ipsilateral parietal cortex is presented in Fig. 1B. Baseline rCBF 
recorded before MCA occlusion under steady-state conditions 
was defined as 100% flow. After MCAO, CBF decreased to 20% 
in both groups. Ischemia was confirmed when the laser Doppler 
signal was reduced to 20% of the baseline. rCBF levels were not 
significantly different between groups. Twenty-four hours after 
MCAO, infarct volume and edema volume were analyzed. Infarct 
volume was markedly reduced to approximately 47% in the IP 
group compared to the EC group at 23 hr of reperfusion follow-
ing 60-min ischemia (Fig. 1C~E). Moreover, IP reduced the brain 
edema significantly at 23 hr of reperfusion following 60-min isch-
emia (Fig. 1F). These results suggest that IP was highly effective in 
protecting the brain from ischemic injury.
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Endogenous agmatine was increased during I/R injury in 
the IP group
The potential relationship between ischemia and endogenous 
agmatine levels was determined in the brain using HPLC analysis 
(Fig. 2). The level of agmatine in normal conditions was 5.65±0.20 
μg/mg protein. It was increased after the onset of MCAO more 
than two-fold to 13.1±1.91 μg/mg protein. After the start of reper-
fusion, agmatine level was decreased to 9.40±1.51 μg/mg protein 
at 1 hr of reperfusion and slowly increased to 15.64±1.53 μg/mg 
protein at 23 hr of reperfusion in the EC group (Fig. 2A). In the IP 
group, the level of agmatine was found to be significantly increased 
(15.35±0.63 μg/mg protein) before the onset of MCAO. Moreover, 
a significantly higher increase (18.92±1.87 μg/mg protein) of ag-
matine was recorded in the IP group compared to that of the EC 
group (9.40±1.51 μg/mg protein) at 1 hr of reperfusion. Agmatine 
level was decreased after 1 hr of reperfusion and reached a plateau 
from 3 hr of reperfusion to 23 hr of reperfusion in the IP group 
(8.83±0.44 μg/mg protein, Fig. 2A). However, the level of agmatine 
in both EC and IP groups was significantly elevated compared to 
the normal level of agmatine. During the IP period before major 
I/R injury, the level of agmatine was significantly increased by 
10-min MCAO in the brain of the IP group (Fig. 2B). The level 
of agmatine was significantly increased in both ipsilateral and 
contralateral hemispheres at 30 min and 1 day after IP. However, 
the level of agmatine was similar in ipsilateral and contralateral 
hemispheres 3 days after IP. The level of agmatine in the liver was 
significantly reduced, showing an opposite tendency to that in the 
brain during 3 days of IP (Fig. 2C). The level of L-arginine in the 
Fig. 2. IP triggers the systemic elevation of agmatine and L-arginine level in rats. (A) The level of agmatine in the rat brain was significantly increased in 
the IP group during MCAO and at the early reperfusion time. The highest peak was noted in the IP group at 2 hr after injury. The level of agmatine was 
gradually reduced in the IP group at 23 hr of reperfusion. However, in the EC group, the agmatine level was gradually in the brain at 23 hr of reperfusion. 
(B) Three days before severe MCAO, experimental animals were subjected to 10-min MCAO. The level of agmatine was significantly increased in the 
ipsilateral and contralateral hemisphere after 10-min IP compared to normal control (NC). The level of agmatine was still intensified about 3.5 folds at 
3 days after IP compared to the normal level of agmatine, but there was no significant difference between ipsilateral and contralateral hemisphere. (C) 
On the other hand, the level of agmatine in liver was significantly reversed after IP. 30 mins after IP, the level of agmatine was significantly reduced about 
20% compared with NC. (D) The level of agmatine precursor, L-arginine, in the liver was significantly suppressed after IP compared with NC. (E) Simul-
taneously, the level of agmatine in plasma and brain was significantly increased at 30 mins after IP. The ratio of agmatine in the plasma was markedly 
increased about ten-fold at 30 min after IP (**p<0.05 vs. EC; ***p<0.01 vs. EC).
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liver was also significantly decreased (Fig. 2D). The more signifi-
cant finding was that plasma agmatine level was significantly in-
creased 30 min after IP, which was synchronized with an increased 
level of agmatine in the brain (Fig. 2B and E).
ADC, the biosynthetic enzyme for agmatine, was upregulated 
in the brain and liver by IP
The expression of ADC in the EC and IP groups was signifi-
cantly upregulated in the ipsilateral brain and liver after cerebral 
ischemia compared to NC (Fig. 3A) and IP increased the expres-
sion of ADC in the liver after cerebral ischemia (Fig. 3B). During 
the IP period, the level of ADC was higher in the ipsilateral brain 
and liver in the IP group compared to NC (Fig. 3A). These results 
indicated that IP led to local ADC upregulation in the brain and 
systemic ADC upregulation in the liver (Fig. 3A and B).
IP reduced nNOS and iNOS expression after cerebral ischemia
Cortical and striatal nNOS expression was significantly reduced 
in the IP group after cerebral ischemia (R23) compared to the EC 
group (Fig. 4A and B). iNOS expression was also decreased in the 
cortex, but not in the striatum, by IP (Fig.4C and D). However, 
immunoreactivity of cortical and striatal iNOS expression was 
significantly reduced in the IP group after cerebral ischemia (R23) 
compared to the EC group (Fig. 4C and D).
DISCUSSION
IP is one of the most important endogenous mechanisms in-
volved in neuroprotection against ischemic or reperfusion injury 
[6, 29-31]. Previous studies have reported two preconditioning 
paradigms: classical and delayed. Classical preconditioning occurs 
within minutes after a brief triggering stimulus and lasts for sev-
eral hours. This phenomenon is related to the direct modulation 
of energy supplies caused by uncoupling of the mitochondria, pH 
regulation, and Na+/Ca2+ homeostasis that reduces Ca2+ uptake 
into the mitochondria. While less protective than classical precon-
ditioning, delayed preconditioning begins 12~24 hr after the trig-
gering stimulus and persists for 2~3 days. Delayed preconditioning 
gives rise to protein kinase C activation of nuclear factor kappa B 
(NF-κB) and other transcription factors and upregulates protec-
tive gene products. For example, induction of heat shock proteins 
reduces the nuclear binding of proinflammatory transcription 
factors, increases the antioxidant capacity of cells [32], prevents 
the activation of intrinsic and extrinsic apoptotic pathways [33], 
and helps repair organs via a chaperone pathway [34]. Regardless 
of what pathways are induced, the essential consequences are that 
both delayed and classical preconditioning decrease energy de-
mand of ischemic tissues [35] and ultimately increase cell survival 
after the insult [36]. Recently, it has been reported that agmatine 
exerts neuroprotection against ischemic injury in neuronal cell 
cultures and experimental stroke in vivo [7, 13]. This neuroprotec-
tion is associated with decreased NOS activity and expression, as 
Fig. 3. Immunoblotting of the level of ADC during and after ischemic injury. (A) The expression level of arginine decarboxylase (ADC) in the ipsilateral 
brain was significantly correlated with the level of agmatine in the brain after IP. (B) Moreover, the expression level of ADC in the liver was significantly 
increased compared to EC after MCAO. EC, experimental control; IP, ischemic preconditioning; 30 min, 30 min after IP; 1 d, 1 day after IP; 3 d, 3 day af-
ter IP; 1 hr, 1 hr after reperfusion; 3 hr, 3 hr after reperfusion; 6 hr, 6 hr after reperfusion; 23 hr, 23 hr after reperfusion (**p<0.05 vs. EC; ***p<0.01 vs. EC).
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well as NO generation [7]. In our previous investigations, we dem-
onstrated that exogenous administration of agmatine rescues reti-
nal ganglion cells from hypoxia and tumor necrosis factor-alpha 
(TNF-α)-induced apoptosis [37, 38]. Agmatine was also reported 
to be involved in increased intracellular tolerance against stress 
conditions, and endogenously synthesized agmatine is increased 
in response to cold-restraint stress [39]. 
Agmatine is synthesized endogenously by ADC from transport-
ed arginine in mitochondria. The ADC activity varies substantially 
across organs, with the highest activities being detected in the liver, 
kidney, and stomach and the lowest activities in the brain and 
adrenal tissues [40]. Moreover, oral administration of agmatine is 
absorbed from the gastrointestinal tract and readily distributed 
throughout the body [41], with a limited amount crossing the 
blood-brain barrier (BBB) [42]. Agmatine analogs that are able to 
cross the BBB have been developed [43]. Previous reports showed 
that agmatine is stored in synaptic vesicles, accumulated by ac-
tive uptake, released by depolarization, and catabolized to form 
putrescine by agmatinase. In the liver and other peripheral tissues, 
agmatine is alternatively oxidized by diamine oxidase. It is then 
converted by aldehyde dehydroxylase to form guanido-butanoic 
acid, which is readily excreted from the body [12].
In this study, we demonstrated that the systemic level of agmatine 
is increased after IP. Furthermore, we suggest a role of agmatine in 
ischemic tolerance. A question was raised regarding the changes 
of the agmatine level in the brain after I/R injury; our data suggest 
that the level of agmatine in the brain was significantly increased 
by IP, yet the level of agmatine was lower in the IP group than 
in the EC group 23 hr after I/R injury. This finding could let us 
explain the time-dependent changes in the agmatine level, which 
may be due to an early response in initial I/R injury that was criti-
cal to the neuroprotective effect in the IP group. However, the level 
of agmatine in the EC group was significantly increased 23 hr after 
I/R injury, which might indicate a delayed protective response 
Fig. 4. Immunohistochemistry of nNOS and iNOS in the ischemic rat brain. (A) nNOS-positive cells (brown) in the ipsilateral brain were significantly 
decreased in the IP group compared with the EC group at 23 hr after reperfusion. (B) Quantification of nNOS-positive cells were analyzed by Image J. 
The nNOS-positive area in cortex and striatum was significantly decreased in the IP group compared to the EC group at 23 hr after reperfusion. (C) The 
expression of iNOS-positive cells (brown) in the IP group was significantly decreased in the cortex and striatum at 23 hr after reperfusion. (D) Quanti-
fication of nNOS-positive cells in the cortex was significantly different between the EC and IP groups, but not in the striatum at 23 hr after reperfusion. 
EC, Experimental control; IP, Ischemic preconditioning, Scale bar is 50 μm (***p<0.01 vs. EC).
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in secondary I/R injury. However, the neurological outcome was 
significantly reduced in the EC group. Another question that was 
raised was regarding the ADC expression; our data suggest that the 
ADC expression during IP and ischemic insult was significantly 
changed in the ipsilateral brain and liver. The significant changes 
occurred alongside with the increased agmatine level in the plas-
ma and brain at 30 min after IP. Moreover, the ratio of L-arginine 
in the liver was significantly reduced at 30 min after IP. These 
results suggest that liver ADC actively metabolized L-arginine and 
secreted agmatine into the plasma after the early phase of IP. Fur-
ther, these results suggest that the local increase of agmatine level 
was not only a consequence of the translational increase of ADC 
expression in the brain but also a result of the systemic induction 
of ADC expression triggered by IP. 
The third question was raised concerning how IP in the brain 
could have systemic effects, including in the liver. Previous reports 
suggest that the benefits of IP on lung IR-induced systemic inflam-
matory response may reflect the protection of both the lungs and 
remote organs. In remote ischemic preconditioning (RIPC), brief 
ischemia of one organ confers protection to distant organs without 
direct stress to the organ. Experimental studies have demonstrated 
that brief I/R of the limb, gut, mesentery, or kidney reduces myo-
cardial infarct size [44]. Furthermore, clinical research has shown 
that skeletal IP induces myocardial protection [44]. Two reports 
have shown that limb IP has a protective role against hepatic IR 
injury in rats [44, 45].The underlying mechanisms and pathways 
of RIPC are not well established, and an overlap between the neu-
rogenic and humoral pathways has been proposed [44]. Remote 
cytokine (including TNF-α [46, 47], interleukin-1 [IL-1] [46], and 
monocyte chemoattractant protein-1 [MCP-1] [48]), NF-κB [49], 
and iNOS [49] modulation through these signaling pathways 
has been suggested as a potential mechanism for RIPC-induced 
protection. It is tempting to speculate that the benefits of IP on 
ischemia-induced systemic inflammatory response may reflect the 
protection of both the target organ and remote organs [50]. These 
reports suggest that the IP-induced systemic pro-inflammatory re-
sponse and anti-apoptotic pathways may reflect the protection of 
both the brain and remote organs. In this study, we proposed that 
ADC and agmatine—typically expressed in the brain and liver—
might be systemically upregulated. Therefore, IP could provide 
systemic protection by upregulating agmatine in the cerebral and 
peripheral system for ischemic tolerance after IP.
From these findings, we suggest that IP triggers endogenous 
agmatine synthesis in the brain and liver, which reduces the brain 
infarct area and edema formation and attenuates the detrimental 
effects of ischemic injury by suppressing nNOS and iNOS expres-
sion.
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